Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

7.7%

11 terminated/withdrawn out of 142 trials

Success Rate

91.3%

+4.8% vs industry average

Late-Stage Pipeline

25%

36 trials in Phase 3/4

Results Transparency

12%

14 of 116 completed trials have results

Key Signals

6 recruiting14 with results9 terminated

Enrollment Performance

Analytics

Phase 1
68(50.7%)
Phase 3
21(15.7%)
Phase 2
19(14.2%)
Phase 4
15(11.2%)
N/A
10(7.5%)
Early Phase 1
1(0.7%)
134Total
Phase 1(68)
Phase 3(21)
Phase 2(19)
Phase 4(15)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (142)

Showing 20 of 142 trials
NCT06725758Phase 1Recruiting

A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours

Role: lead

NCT06136650Phase 3Recruiting

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Role: collaborator

NCT06136624Phase 3Recruiting

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Role: collaborator

NCT07563738Phase 1Recruiting

A 2-part Phase 1/2 Open-label Trial on ODM-212

Role: lead

NCT06104449Phase 1Completed

A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)

Role: collaborator

NCT06353386Phase 1Recruiting

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

Role: collaborator

NCT06136598Phase 1Completed

A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)

Role: collaborator

NCT04736199Phase 3Completed

Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer

Role: collaborator

NCT02799602Phase 3Completed

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

Role: collaborator

NCT06956495Phase 2Completed

Efficacy and Tolerability of Tasipimidine in Sleepless Patients

Role: lead

NCT05664191Phase 2Recruiting

Levosimendan as Treatment of Aneurysmal SubArachnoid Haemorrhage

Role: collaborator

NCT03436485Phase 1Active Not Recruiting

Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer

Role: lead

NCT03368118Phase 2Completed

Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis

Role: collaborator

NCT02965898Not ApplicableCompleted

The Effect of Vitamin D Substitution on the Development of Chronic Pancreatitis

Role: collaborator

NCT04869384Phase 4Completed

Effect of Electronic Monitoring and Feedback on Adherence to Easyhaler Controller Medication in Patients With Asthma

Role: lead

NCT06566989Phase 1Completed

A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)

Role: collaborator

NCT03878823Phase 1Completed

Safety and Pharmacokinetics of ODM-209

Role: lead

NCT04225884Not ApplicableCompleted

Digital Therapeutics (DTx) for Pain: Pilot Study of a Virtual Reality Software for Chronic Pain

Role: lead

NCT05811039Not ApplicableCompleted

Efficacy and Safety of Remo-Wax® Oil (RWO) in Subjects With Isolated Itching of the External Ear Canal

Role: lead

NCT05084222Phase 4Completed

Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing

Role: lead